AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
BPOP Popular Inc
BGS B&G Foods Inc
LEGAU Lead Edge Growth Opportunities Ltd
TGT Target Corp
GLBLU Cartesian Growth Corp
FCRD First Eagle Alternative Capital BDC Inc
RWAY Runway Growth Finance Corp
LITB LightInTheBox Holding Co Ltd
UEC Uranium Energy Corp
Go

Health Care : Pharmaceuticals | Large Cap Growth
Based in United Kingdom
Company profile

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$58.85
Day's Change
0.75 (1.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.99
Day's Low
58.17
Volume
(Heavy Day)
Volume:
5,013,799

10-day average volume:
4,100,494
5,013,799

Display:

Providers:

UpdateCancel
6 providers
January 13, 2022
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI(R) (durvalumab) and LYNPARZA(R) (olaparib) Data at ASCO GI and GU

--LYNPARZA combined with abiraterone will demonstrate clinical benefit regardless of biomarker status in metastatic castration-resistant prostate cancer AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its...(BusinessWire)

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

AstraZeneca and Amgen today announced TEZSPIRE(TM) (tezepelumab-ekko) is now available for shipment to wholesalers in the US. TEZSPIRE was approved by the US Food and Drug Administration (FDA) on December 17, 2021 for the add-on maintenance...(BusinessWire)

January 10, 2022
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...(PR Newswire)

December 23, 2021
Thinking about trading options or stock in Tesla, Scientific Games, Novavax, Moderna, or AstraZeneca?

InvestorsObserver issues critical PriceWatch Alerts for TSLA, SGMS, NVAX, MRNA, and AZN. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities

--Only antibody authorized in the US for pre-exposure prophylaxis of COVID-19 AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralization activity...(BusinessWire)

December 16, 2021
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical...(BusinessWire)

December 13, 2021
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership is based on an...(PR Newswire)

December 12, 2021
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial

Updated results from the ASCEND Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit at three years compared to investigator's choice of rituximab combined...(BusinessWire)

December 09, 2021
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer

New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated a higher progression-free survival (PFS) and objective response rate (ORR) in pre-specified patient subgroups compared to...(BusinessWire)

December 03, 2021
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

--Extensive portfolio of nine approved and potential new medicines to be featured across subtypes and stages of disease, including data for novel combinations AstraZeneca will underscore its ambition to redefine care with new data from across its...(BusinessWire)

AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

--Extensive portfolio of nine approved and potential new medicines to be featured across subtypes and stages of disease, including data for novel combinations AstraZeneca will underscore its ambition to redefine care with new data from across its...(BusinessWire)

November 19, 2021
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

Deutsche Bank today announced that the presentations from the November 16th and 17th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies...(PR Newswire)

November 12, 2021
Thinking about trading options or stock in Microsoft, Nio, Carlyle Group, AstraZeneca, or Gilead Sciences?

InvestorsObserver issues critical PriceWatch Alerts for MSFT, NIO, CG, AZN, and GILD. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

November 11, 2021
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021

Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 16 and Wednesday, November 17, featuring live webcast presentations from international companies with American Depositary...(PR Newswire)

November 05, 2021
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

--New CALQUENCE tablet formulation will potentially expand eligible patient population with comparable efficacy and safety to current capsules --Emerging pipeline will also demonstrate promise of inducing deeper patient responses using novel...(BusinessWire)

November 03, 2021
Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for...(PR Newswire)

November 01, 2021
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities

--Recipient organizations from all across the country will deliver programs that take a community-based approach to improve local health outcomes AstraZeneca is proud to announce contributions to 30 nonprofit, community-based organizations...(BusinessWire)

October 25, 2021
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis

Positive high-level results from the TOPAZ-1 Phase III trial showed IMFINZI(R) (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus...(BusinessWire)

October 20, 2021
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards

AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards (or C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate diverse individuals and...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.